Kate Haviland’s Post

𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐚𝐧𝐝 𝐏𝐡𝐚𝐫𝐦𝐚 𝐔𝐩𝐝𝐚𝐭𝐞𝐬: September 25 - 26, 2024 (Get the full list of 30 news pieces in today's TLDR Biotech newsletter: https://lnkd.in/gKxuKwXw) • Bristol Myers Squibb’s historic schizophrenia FDA approval • ARCH Venture Partners $3B 13th fund • Genentech touts positive Ph3 Gazyva lupus data • CSL Seqirus nabs another BARDA bird flu contract • Mirai Bio launches as Flagship Pioneering’s newest endeavour • Novo Nordisk & Evotec partner to develop off-the-shelf stem-cell derived cell therapies • Inventiva Pharma’s coffers are weeks from running dry • Biogen and Sage Therapeutics discontinue essential tremor partnership • FDA adcomm advises narrower PD-1 inhibitor approvals • Top NIH neuroscientist conducted alleged widespread Parkinson’s & Alzheimer's research misconduct #biotech #pharma #pharmanews #biotechnews #tldrbiotech

Sanofi pays $110M upfront for late-stage radioligand therapy, setting up rivalry with Novartis. Sanofi has made a late entry to the radioligand party, paying 100 million euros ($110 million) upfront for global rights to a neuroendocrine tumor treatment that is nearing a filing for approval. The French drugmaker has stayed on the sidelines as a who’s who of drugmakers, led by Novartis, have placed big bets on radioligand therapies. Sanofi is entering the sector through a deal with Radiomedix, Inc. and Orano Med for a targeted alpha... Check out the full story 👉 https://zurl.co/iia1 (Fierce Biotech) #biotech #genetics

Imagine Biotech calls upon an extremely diverse team of experts with extensive training and knowledge to review the proposed hypotheses (investment) of drug therapeutics throughout the entire journey from conception to commercialization. Selecting tests/technologies to support further investment success or flag issues can only be accomplished in the review environment of highly skilled biotechnology experts. Depending on which sector (antibiotics, oncology, metabolic, diagnostic), certain assets are selected as components of the report we generate for investors and, in some cases, cost less than legal reviews.

SFBN Feed: Cancer drug from Peninsula company wins FDA advisory committee thumbs up https://lnkd.in/dMNJ_Fkq The decision moves Geron closer to its first drug approval in its three decades. Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks #BayArea #SanFrancisco #Biotech #Lifescience #News

ICYMI: We’re looking for researchers across academia and industry to propose to our new Hermes effort to streamline delivery modalities for #biologic #therapeutics. Efforts to develop novel biologic therapeutics have provided critical resources to enable warfighter readiness and counter existing and emerging biothreats; however, current delivery modalities limit biologics’ efficacy and rapid deployment. The goal of DARPA’s new Hermes program is to overcome the challenges associated with broad, intracellular delivery of biologics to diverse cell and tissue types by developing new delivery modalities that provide systemic distribution with limited negative side effects. A draft Broad Agency Announcement is now available: https://lnkd.in/e2MJexjd

Commit Biologics welcomes Mikkel Wandahl Pedersen, as its new Chief Scientific Officer🚀   With over two decades of experience in #antibody-based drug discovery and development, Mikkel further strengthens our leadership team as we continue to advance our Bispecific Complement Engaging (#BiCE™) technology, designed to revolutionise treatments for #cancer and #autoimmune disease. 💊   Mikkel joins us from Nykode Therapeutics where, as CSO, he successfully created and executed a new research strategy, scaled the research organisation to support an expanding pipeline, and spearheaded key collaborations with external pharmaceutical partners.   He brings to Commit a wealth of knowledge in #immunooncology and #autoimmune research   To learn more about Mikkel's background see the press release, linked in the comments below 👇.   #CSO #Leadership #ComplementSystem

🗣 💹 A mixed week to report in the biotech space! Here's some of the latest headlines.... ✅ Medtronic spinal cord simulator gets FDA approval ✅ AI progress for peptide drug discovery University of Washington ✅ Irregular heartbeat solution created by Boston Scientific accelerates electrophysiology sales by 70% ✅ Regeneron pens Gene Editing deal worth close to $500M with Mammoth Biosciences ✅ Pfizer and CeMM collab leads to new small molecule AI-driven drug discovery methods after 3 years of research ❌ $1.5B restructuring effort leads to closure of Bristol Myers Squibb site in Redwood City, CA ❌ Gilead Sciences suffers ~ $5B loss on solid tumor drug pipeline ❌ 4 out of 7 assets slashed by new management at BioMarin Pharmaceutical Inc. Big pharma suffers once again but lots of positives to take in terms of continued scientific progress and breakthroughs across the industry. What else is new lately? Comment below ⤵ ⤵ ⤵ ⤵

Odyssey Therapeutics Appoints William Roush, Ph.D., as EVP and Head of Small Molecule Research Learn more & get our take 👇 https://lnkd.in/gaApD7Ut “As a renowned scientist, Dr. Roush developed innovative solutions to complex problems in organic and medicinal chemistry, and under his leadership, has led multiple drug discovery programs from ideation into clinical development.” — Gary D. Glick, Ph.D., Founder and CEO at Odyssey Therapeutics “By collaborating with others at Odyssey, I hope to accelerate the discovery and development of small molecule medicines to enhance the quality of life for patients.” — Dr. William Roush, Executive Vice President and Head of Small Molecule Research at Odyssey Therapeutics #Biotech #Therapeutics #SoHCNews

𝗖𝗮𝗻𝗰𝗲𝗿 𝗝𝗮𝗻𝘂𝘀 𝗞𝗶𝗻𝗮𝘀𝗲 𝗜𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝟮𝟬𝟮𝟰-𝟮𝟬𝟯𝟭. 𝗚𝗹𝗼𝗯𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗲𝗽𝗼𝗿𝘁 The research report encompasses an overview of the development of the Cancer Janus Kinase Inhibitors industry chain, focusing on its applications in Hospitals (Ruxolitinib, Momelotinib) and Ambulatory Surgical Centers (Ruxolitinib, Momelotinib). It highlights key enterprises in both developed and developing markets while analyzing cutting-edge technology, patents, hot applications, and market trends of Cancer Janus Kinase Inhibitors. 𝐓𝐨 𝐊𝐧𝐨𝐰 𝐭𝐡𝐞 𝐆𝐥𝐨𝐛𝐚𝐥 𝐒𝐜𝐨𝐩𝐞 𝐚𝐧𝐝 𝐃𝐞𝐦𝐚𝐧𝐝 𝐨𝐟 𝗖𝗮𝗻𝗰𝗲𝗿 𝗝𝗮𝗻𝘂𝘀 𝗞𝗶𝗻𝗮𝘀𝗲 𝗜𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀 𝗠𝗮𝗿𝗸𝗲𝘁. 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅: https://lnkd.in/guSqh8-w *𝗕𝘆 𝗧𝘆𝗽𝗲: Ruxolitinib, Momelotinib, Lestaurtinib, Pacritinib, *𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: Hospitals, Ambulatory Surgical Centers, Others *𝗕𝘆 𝗥𝗲𝗴𝗶𝗼𝗻: North America, Europe, Asia-Pacific, South America, Middle East & Africa *𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: Abbott, Asana BioSciences, LLC, AstraZeneca, Celonic Group, Dynamic Pharma S.A. – Δυναμική Φαρμακαποθήκη Α.Ε., Eli Lilly and Company, Gilead Sciences, Hanmi Pharmaceuticals, Incyte, Kyowa Hakko USA, Moleculin Biotech, Inc., Pfizer, Portola Pharmaceuticals #januskinaseinhibitors #cancerresearch #cancertreatment #oncology #drugdevelopment #cancertherapeutics #pharmaceuticals #biomedicalscience #jakinhibitors #precisionmedicine

🎥 IN CASE YOU MISSED IT | Rakovina Therapeutics Executive Chairman Jeffrey Bacha discusses #RKV's novel low-cost #drugdevelopment and partnering strategy targeting DNA-damage response inhibitors. Watch the interview here ➡ https://lnkd.in/giWETwBM #CancerResearch #DNAResponse #CancerTreatment #OncologyInnovation #Biotech #CancerTherapeutics #AI